drug_type
RELEVANT_DRUG
intervention_type
Biological (Cellular Immunotherapy)
drug_description
An intrathecal, autologous dendritic cell (DC1) vaccine loaded with HER2 and HER3 peptides to present tumor antigens and prime/activate tumor-specific T cells (Th1/CTL) within the cerebrospinal fluid for immune-mediated killing of cancer cells in leptomeningeal disease from TNBC or HER2+ breast cancer.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Cancer Vaccines
drug_category
DC VACCINE
drug_class
Vaccine
drug_delivery_route
Intrathecal
drug_mechanism_of_action
Autologous DC1 dendritic cells pulsed with HER2/HER3 peptides are administered intrathecally to present these antigens via MHC to T cells in the CSF, inducing Th1 polarization and priming/activating tumor‑specific CD4+ and CD8+ cytotoxic T cells to recognize and kill HER2/HER3‑expressing leptomeningeal tumor cells.
drug_name
Dendritic Cell Vaccine (DC1) pulsed with HER2/HER3 peptides
nct_id_drug_ref
NCT05809752